Hypertension Drugs Market 2016-2020

This market research report presents a detailed segmentation of the global hypertension drugs market by type (systemic hypertension drugs and pulmonary hypertension drugs) and by geography (Americas, APAC, and EMEA). Some of the vendors in the market are Novartis, Daiichi Sankyo, Actelion Pharmaceuticals, Boehringer Ingelheim, Sanofi, and AstraZeneca.

The outlook of the hypertension drugs market

Extensive research carried out by the analysts at Technavio has shown that the global hypertension drugs market will post an impressive market value of USD 32 billion by the end of 2020. With an increase in the population of older people, the market for hypertension drugs has a positive outlook over the forecast period. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60. Currently, close to 11% of the global population is aged 60 years or over and is estimated to reach nearly 22% by 2050. Since the risk of developing pulmonary hypertension increases with age, a growing older population will aid in the growth prospects of the hypertension drugs market size in the coming years. 

Hypertension drugs market drivers

In this industry research report, the analysts have estimated factors like the growing awareness of hypertension and it's treatment options to impel this market’s growth prospects until the end of 2020.  Enhanced patient awareness results in an early diagnosis of the disease followed by treatment. For instance, the National Heart, Lung, and Blood Institute of National Institutes of Health launched the High Blood Pressure Education program which is a cooperative effort among professionals, voluntary health agencies, and state health departments with a goal to cut down death and disability related to hypertension through several professional programs, patient interaction, and public education. Similarly, 17th May is celebrated as the World Hypertension Day every year by the International Society of Hypertension. Such events and resources increase awareness among people and are expected to drive the market growth for hypertension drugs during the forecast period.

Hypertension drugs market segmentation by type

• Systemic hypertension drugs
• Pulmonary hypertension drugs

During 2015, the systemic hypertension drugs segment dominated the hypertension drugs market and accounted for close to 87% of the market share. However, the market segment is expected to witness a decline in the forecast period because of patent expiries of drugs, followed by generic erosion. The systemic hypertension drugs market is expected to reach more than USD 27 billion by the end of 2020.

Hypertension drugs market based on geographical segmentation 

• Americas
• APAC
• EMEA

In 2015, the Americas was the largest market for hypertension drugs as it accounted for more than 44% of the market share. The US is the major revenue contributor in the region. The market share is declining due to the patent expiries of drugs such as Micardis, Avapro, and Diovan. However, comorbid conditions among the older population like congenital heart disease and increasing focus on combination therapies will prevent the decline in the market. Moreover, the launch of new disease-modifying therapies is expected to bolster the growth prospects of the market during the forecast period.

Hypertension drugs market: Competitive landscape and key vendors

The global market for the hypertension drugs is high consolidated due to the presence of a few well-established vendors. At present, the market is declining because of the increased use of generic drugs. Therefore, companies are investing heavily in the development of new medicines for the treatment of hypertension.

Key vendors in the hypertension drugs market

• Novartis
• Daiichi Sankyo
• Actelion Pharmaceuticals
• Boehringer Ingelheim
• Sanofi
• Pfizer

Other prominent vendors in the market are Actelion Pharmaceuticals, Arena Pharmaceuticals, Asahi Kasei, Bayer HealthCare, Bellerophon Therapeutics, Bial, CJ HealthCare, Conatus Pharmaceuticals, Deka Pharmaceuticals, Dong-A ST, Eiger BioPharmaceuticals, Forest Laboratories, Gilead Sciences, HanAll BioPharma, Hanmi Pharmaceutical, Johnson & Johnson, LG Life Sciences, Lung Biotechnology, Lupin Pharmaceuticals, Mast Therapeutics, Merck, Northern Therapeutics, Ono Pharmaceutical,

Pfizer, PhaseBio, Pluristem Therapeutics, Quantum Genomics, Radikal Therapeutics, Reata Pharmaceuticals, Serodus, sigma-tau i.f.r, SteadyMed Therapeutics, Suda, Sun Pharmaceutical Industries, Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, and Yuhan.

Key questions answered in the report include

• What will the hypertension drugs market size and growth rate be in 2020?
• What are the key factors driving the global hypertension drugs market?
• What are the key market trends impacting the growth of the global hypertension drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global hypertension drugs market?
• What are the market opportunities and threats faced by the vendors in the global hypertension drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global hypertension drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Pulmonary Hypertension - Global Market Research 2015-2019
• Anti-obesity Drugs Market in the US 2015-2019
• Global Respiratory Drugs Market 2016-2020
• Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019